← Back
SAN GIOVANNI
December, 06th | 11:00 - 12:30
RETINA FUTURA - SESSION 1 - Unconditional support of Ocular Therapeutix
Add to calendar
Chairs: RIZZO STANISLAO, HEIER JEFFREY S., KAISER PETER, VAJZOVIC LEJLA
Wet Age-Related Macular Degeneration (wAMD): Emerging Therapies and Clinical Updates
December, 06th | 11:05 - 11:09
EB-105: A Novel Trispecific Fusion Antibody for Retinal Disease
AWH CARL
Add to calendar
EB-105: A Novel Trispecific Fusion Antibody for Retinal Disease
AWH CARL
Add to calendar
December, 06th | 11:09 - 11:13
Impact of GLP-1 Receptor Agonists on Chronic Eye Conditions Including Non-Exudative AMD
RACHITSKAYA ALEKSANDRA
Add to calendar
Impact of GLP-1 Receptor Agonists on Chronic Eye Conditions Including Non-Exudative AMD
RACHITSKAYA ALEKSANDRA
Add to calendar
December, 06th | 11:13 - 11:17
Glibenclamide is Neuroprotectant Against AMD
BEHAR COHEN FRANCINE
Add to calendar
Glibenclamide is Neuroprotectant Against AMD
BEHAR COHEN FRANCINE
Add to calendar
December, 06th | 11:17 - 11:21
An overview of ONS-5010 (bevacizumab gamma) as ophthalmic formulation of bevacizumab
AUGUSTIN ALBERT
Add to calendar
An overview of ONS-5010 (bevacizumab gamma) as ophthalmic formulation of bevacizumab
AUGUSTIN ALBERT
Add to calendar
December, 06th | 11:21 - 11:25
EYP-1901 for Maintenance Treatment of Neovascular AMD: Phase 2 DAVIO 2 End-of-Study 12-Month Results
REGILLO CARL D.
Add to calendar
EYP-1901 for Maintenance Treatment of Neovascular AMD: Phase 2 DAVIO 2 End-of-Study 12-Month Results
REGILLO CARL D.
Add to calendar
December, 06th | 11:25 - 11:29
Beyond VEGF-A inhibition: will blocking VEGF-C and VEGF-D lead to better outcomes?
TUFAIL ADNAN
Add to calendar
Beyond VEGF-A inhibition: will blocking VEGF-C and VEGF-D lead to better outcomes?
TUFAIL ADNAN
Add to calendar
December, 06th | 11:29 - 11:33
OTX-TKI–The Evolution of Optimized AXPAXLI (AUS >> US >> SOL-1)
DO DIANA V.
Add to calendar
OTX-TKI–The Evolution of Optimized AXPAXLI (AUS >> US >> SOL-1)
DO DIANA V.
Add to calendar
Innovations in siRNA and Gene Therapies for AMD
December, 06th | 11:45 - 11:49
Gene Therapy for Neovascular AMD by Subretinal and Suprachoroidal Delivery of ABBV-RGX-314 Including Fellow Eye Data
BAKRI SOPHIE J.
Add to calendar
Gene Therapy for Neovascular AMD by Subretinal and Suprachoroidal Delivery of ABBV-RGX-314 Including Fellow Eye Data
BAKRI SOPHIE J.
Add to calendar
December, 06th | 11:49 - 11:53
Efficacy and Safety of Ixoberogene Intravitreal Gene Therapy for Neovascular AMD: Phase 2 LUNA Trial Study Results
FISCHER DOMINIK
Add to calendar
Efficacy and Safety of Ixoberogene Intravitreal Gene Therapy for Neovascular AMD: Phase 2 LUNA Trial Study Results
FISCHER DOMINIK
Add to calendar
December, 06th | 11:53 - 11:57
First Results of the Phase 2 BETTER Trial Using Intravitreal ISTH0036: a Selective TGF-β2–Blocking Antisense in AMD and DME
MUNK MARION
Add to calendar
First Results of the Phase 2 BETTER Trial Using Intravitreal ISTH0036: a Selective TGF-β2–Blocking Antisense in AMD and DME
MUNK MARION
Add to calendar
December, 06th | 11:57 - 12:01
Development of 4D-150 for Retinal Vascular Diseases
QUEZADA RUIZ CARLOS
Add to calendar
Development of 4D-150 for Retinal Vascular Diseases
QUEZADA RUIZ CARLOS
Add to calendar
Spotlight on Inherited Retinal Diseases (IRDs)
December, 06th | 12:10 - 12:14
Gildeuretinol Slows Progression of Stargardt Disease: The TEASE Program
FERRONE PHILIP
Add to calendar
Gildeuretinol Slows Progression of Stargardt Disease: The TEASE Program
FERRONE PHILIP
Add to calendar
December, 06th | 12:14 - 12:18
Subretinal Gene Therapy AGTC-501 for X-Linked Retinitis Pigmentosa (XLRP) Phase 2 Multicenter Study (DAWN): Preliminary Result
STANGA PAULO EDUARDO
Add to calendar
Subretinal Gene Therapy AGTC-501 for X-Linked Retinitis Pigmentosa (XLRP) Phase 2 Multicenter Study (DAWN): Preliminary Result
STANGA PAULO EDUARDO
Add to calendar
December, 06th | 12:18 - 12:22
Longitudinal Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients With Severe Vision Loss Due to Retinitis Pigmentosa: 126-Week Results From a Long-Term Follow-Up Study (REMAIN)
MONES JORDI
Add to calendar
Longitudinal Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients With Severe Vision Loss Due to Retinitis Pigmentosa: 126-Week Results From a Long-Term Follow-Up Study (REMAIN)
MONES JORDI
Add to calendar
